m+Medelevator.RU
← Поиск публикаций
Nature communications · 2026

Rapid Whole Genome Sequencing Enhances Pediatric Cancer Diagnosis.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Vedi Aditi, Trotman Jamie, Dias Joao M L, Mijuskovic Martina, Choi Sera, Kingham Laura, Moore Rachel A, Leiter Sarah M, Guermech Rowena, Semerene Amanda, Grisby Aviva, Wool Sophie, Joslin Victoria, Mahendrayogam Arunthethy, Abrams Jonathan, Gattens Michael, Blanco Esther, Dickens Emmy L, Burns Charlotte, Murray Matthew J, Tadross John A, Trayers Claire, Hook Catherine E, Becq Jennifer, Newington Taksina, Armogida Ivana, Kingsbury Zoya, Grobecker Pascal, Vitoriano Ines, Bekritsky Mitchell A, Weir Jacqueline, Fraser Louise J, Ross Mark, Bentley David, Cullen Matthew, Behjati Sam, Bartram Jack, Humphray Sean J, Tarpey Patrick, Rowitch David

Аннотация

Whole-genome sequencing (WGS) has been shown to improve diagnosis beyond standard-of-care genetic tests and guide precision treatment for childhood cancer. While WGS is now offered for children with suspected cancer in England, clinical workflows typically return results after several weeks whereas clinical decisions are often required within days. Here we evaluate feasibility and efficacy of a rapid WGS (rWGS) research workflow with streamlined bioinformatics to deliver clinical genomic findings (NCT07201038, Active, not recruiting). In 54 children with suspected or confirmed malignancy, rWGS reduces mean end-to-end turnaround time from 42 to 3 days, whilst increase variant detection rate. Whereby rWGS detected 147 of 155 (95%) clinically actionable variants identified in the cohort, standard of care testing detected 138 of 155 (89%) variants. In a subset of 35 patients assessed prospectively, clinicians report that in 17 (49%), rWGS either (i) facilitates faster access to targeted therapy and risk stratification, or (ii) avoids unnecessary investigations and treatment escalation. These findings indicate feasibility and suggest clinical utility of rWGS when deployed as a first line diagnostic test in pediatric oncology.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты